Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic

Bone Marrow Transplantation

Volumn 47, Issue 11, 2012, Pages 1391-1396

  Beksac, M ^a   Preffer, F ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

aldehyde dehydrogenase; CD133; CD34; flow cytometry; hematopoietic SCT

Indexed keywords

5' NUCLEOTIDASE; ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD135 ANTIGEN; CD146 ANTIGEN; CD150 ANTIGEN; CD34 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; DYE; ENDOGLIN; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN;

ANTIGEN DETECTION; ANTIGEN FUNCTION; CANCER STEM CELL; CD34 SELECTION; CELL COUNT; CELL SUBPOPULATION; CELL VIABILITY; CLINICAL ASSESSMENT; COLONY FORMING UNIT; EMBRYO DEVELOPMENT; ENGRAFTMENT; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; NEUTROPHIL ENGRAFTMENT; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PLATELET ENGRAFTMENT; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; REVIEW; STEM CELL MOBILIZATION; STEM CELL SUBPOPULATION QUANTIFICATION METHOD;

ANIMALS; ANTIGENS, CD34; CELL DIFFERENTIATION; FLOW CYTOMETRY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 84869097669     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.240     Document Type: Review

References (57)

1. Thomas ED, Lochte Jr HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-496.
2. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony stimulating factor mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft versus host disease after human antigen identical sibling transplantation. Blood 2001; 98: 3221-3227.
3. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34 cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
4. McKenzie J, Gan O, Doedens M, Wang JCY, Dick JE. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nature Immunol 2006; 7: 1225-1233. (Pubitemid 44594319)
5. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood stem cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377. (Pubitemid 30159857)
6. Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 2003; 31: 839-845. (Pubitemid 36675738)
7. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demier T, Sanders J et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995; 85: 1655-1658.
8. + cell dose in autologous peripheral-blood stem-cell transplantation. J Clin Oncol 2000; 18: 3319-3320.
9. + cell dose in patients undergoing autologous hematopoietic SCT for myeloma? Bone Marrow Transplant 2009; 43: 301-305.
10. + cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-972. (Pubitemid 34845951)
11. Lazarus HM, Haynesworth SE, Gerson SL, Caplan AI. Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections. J Hematother 1997; 6: 447-455.
12. Haas R, Murea S. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells. Cytokines Mol Ther 1995; 1: 249-270. (Pubitemid 3018452)
13. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150: 647-662.
14. Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behaviour of hematopoietic stem cells. Cell 1986; 45: 917-927. (Pubitemid 16083695)
15. Gronthos S, Zannettino AJW, Hay SJ, Shi S, Graves SE, Kortesidis A et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003; 116: 1827-1835. (Pubitemid 36582169)
16. Chamberlain G, Fox J, Ashton B, Middleton J. Concise Review: Mesenchymal Stem Cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749. (Pubitemid 350127858)
17. Allison MR, Islam S. Attributes of adult stem cells. J Pathology 2009; 217: 144-160.
18. He Q, Wan C, Li G. Multi-potent mesenchymal stromal cells in blood. Stem Cells 2007; 25: 69-77. (Pubitemid 46052976)
19. Tarnok A, Ulrich H, Bocsi J. Phenotypes of stem cells from diverse origin. Cytometry 2010; 77A (Part A): 6-10.
20. Preffer F, Dombkowski D. Advances in complex multiparameter flow cytometry technology: applications in stem cell research. Cytometry 2009: Part B (Clinical Cytometry) 76B: 295-314.
21. Ratajczak MZ. Phenotypic and functional characterization of hematopoietic stem cells. Current Opin Hematol 2008; 15: 293-300.
22. + cells and late hematopoietic reconstitution after autologous peripheral blood stem cell transplantation. Leuk Lymph 2004; 45: 661-668. (Pubitemid 38258181)
23. +CD38-bone marrow cells in Myelodysplastic Syndromes. Cytometry A 2010; 77: 840-848.
24. Sonoda Y. Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: The significance of the intra-bone marrow injection. J Autoimmun 2008; 30: 136-144.
25. + cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 2001; 114: 937-943. (Pubitemid 32953758)
26. + cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haem 2002; 117: 238-244. (Pubitemid 34304449)
27. + progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 1386-1393.
28. + hematoprogenitor cells for hematopoietic grafting. Transfusion 2009; 49: 532-535.
29. Fallon P, Gentry T, Balber AE, Boulware D, Ianssen WE, Smilee R et al. Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol 2003; 122: 99-108. (Pubitemid 36819344)
30. Lioznov MV, Freiberger P, Kroger N, Zander AR, Fehse B. Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone marrow Transplant 2005; 35: 909-914. (Pubitemid 40667634)
31. Gunduz E, Demirel G, Bal C, Gulbas Z. Evaluation of mobilized peripheral stem cells according to CD34 and aldehyde dehydrogenase expression and effect of SSC lo ALDH br cells on hematopoietic recovery. Cytotherapy 2010; 12: 1006-1012.
32. +) compartment. Bone Marrow Transplant 2011; 46: 650-658.
33. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008; 214: 3-9.
34. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012. (Pubitemid 28007217)
35. Christ O, Lucke K, Imren S, Leung K, Hamilton M, Eaves A et al. Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica 2007; 92: 1165-1172. (Pubitemid 350144173)
36. + quiescent cells. Bone Marrow Transplant 2009; 43: 627-635.
37. Storms RW, Green PD, Safford KM, Niedzwiecki D, Cogle CR, Colvin OM et al. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood 2005; 106: 95-102. (Pubitemid 40967179)
38. Povsic TJ, Zavodni KL, Kelly FL, Zhu S, Goldschmidt-Clermont PJ, Dong C et al. Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Col Cardiol 2007; 50: 2243-2248. (Pubitemid 350166817)
39. Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Czeer MH et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104: 1648-1655. (Pubitemid 39202270)
40. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806. (Pubitemid 26134320)
41. Preffer FI, Dombkowski D, Sykes M, Scadden D, Yang YG. Lineage-negative sidepopulation (SP) cells with restricted hematopoietic capacity circulate in normal human adult blood: immunophenotypic and functional characterization. Stem Cells 2002; 20: 417-427.
42. + CD38 stem/progenitor cell compartment. Stem Cells 2009; 27: 2552-2562.
43. Pearce DJ, Bonnet D. The combined use of Hoechst efflux ability and aldehyde dehydrogenase activity to identify murine and human hematopooietic stem cells. Exp Hematol 2007; 35: 1437-1446. (Pubitemid 47302593)
44. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011; 7: 292-306.
45. + cells through Wnt signaling. Nat Immunol 2007; 8: 1123-1131. (Pubitemid 47423760)
46. Alison MR, Guppy NJ, Lim SML, Nicholson LJ. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol 2010; 222: 335-344.
47. Canaani J, Kollet O, Lapidot T. Neural regulation of bone, marrow, and the microenvironment. Front Biosci (Schol Ed) 2011; 3: 1021-1031.
48. Lord BI, Testa NG, Hendry JH. The relative spatial distributions of CFUs and CFUc in the normal mouse femur. Blood 1975; 46: 65-72.
49. Taichman RS, Reilly MJ, Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood 1996; 87: 518-524. (Pubitemid 26030307)
50. Gong JK. Endosteal marrow: a rich source of hematopoietic stem cells. Science 1978; 199: 1443-1445. (Pubitemid 8301986)
51. Tolar J, Villeneuve P, Keating A. Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 2011; 22: 257-262.
52. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317. (Pubitemid 44269669)
53. Broxmeyer HE, Cooper S, Hass DM, Hathaway JK, Stehman FB, Hangoc G. Experimental basis of cord blood transplantation. Bone Marrow Transplant 2009; 44: 627-633.
54. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011; 117: 2332-2339.
55. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 2011; 108: 5009-5014.
56. Rhee WJ, Bao G. Simultaneous detection of mRNA and protein stem cell markers in live cells. BMC Biotechnol 2009; 9: 30-40.
57. Awan A, Oliveri RS, Jensen PL, Christensen T, Andersen CY. Immunoflourescence and mRNA Analysis of Human Embryonic Stem Cells (hESCs) grown under feederfree conditions. In: Turksen K. (ed). Human Embryonic Stem Cell Protocols, Methods in Molecular Biology. Humana Press: New York, NY, USA, 2010, pp 195-210.